Treatment Duration clinical trials

Explore recruiting treatment duration clinical trials.

Recruiting treatment duration studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Treatment Duration trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

SAFE study

Netherlands

Therapeutic confirmatory (Phase III) EU CTIS Study details

Prospective, multistage, two-arm, randomised, double-blind study on the efficacy and safety of treatment of mild to moderate actinic keratosis with a 5% potassium hydroxide solution versus placebo with different duration of treatment cycles

Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

CUSTOMIZED ANTIBIOTIC TREATMENT DURATION AMONG HOSPITALIZED PATIENTS WITH MODERATELY SEVERE COMMUNITY-ACQUIRED PNEUMONIA [CAT-CAP]

France

Therapeutic confirmatory (Phase III) EU CTIS Study details

A multicenter, randomized, double-blind, placebo-controlled, adaptive, non-inferiority trial to investigate shortening treatment duration in uncomplicated candidemia: the CanTEN trial

Germany

Therapeutic use (Phase IV) EU CTIS Study details

GFM-ONUVEN-MDS : A phase I/II, open-label, single arm, multicenter dose-finding study to assess the safety and preliminary efficacy of Oral Azacitidine CC-486 (ONUREG®) in combination with Venetoclax (VENCLYXTO®) in previously untreated higher-risk myelodysplastic syndromes ineligible for allogenic transplantation

France

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Double-blind, randomized, active-controlled, two-way cross-over study, with 12-week treatment duration per period, to evaluate the efficacy and safety of QMF149 (indacaterol acetate / mometasone furoate) compared to budesonide in children from 6 to less than 12 years of age with asthma

Portugal, Hungary, Greece, Spain, Romania, Czechia +3 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Treatment Duration trials by city

Treatment Duration in Toronto Treatment Duration in Vancouver Treatment Duration in Montreal Treatment Duration in Calgary Treatment Duration in Edmonton Treatment Duration in Ottawa Treatment Duration in Winnipeg Treatment Duration in Quebec City Treatment Duration in Hamilton Treatment Duration in Kitchener Treatment Duration in London Treatment Duration in Halifax Treatment Duration in New York Treatment Duration in Los Angeles Treatment Duration in Chicago Treatment Duration in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease